SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-005188
Filing Date
2024-01-09
Accepted
2024-01-09 16:01:57
Documents
16
Period of Report
2024-01-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d703135d8k.htm   iXBRL 8-K 35062
2 EX-4.1 d703135dex41.htm EX-4.1 68226
3 EX-5.1 d703135dex51.htm EX-5.1 13855
4 EX-10.1 d703135dex101.htm EX-10.1 163297
8 GRAPHIC g703135g0108142804737.jpg GRAPHIC 2091
  Complete submission text file 0001193125-24-005188.txt   482003

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA atra-20240108.xsd EX-101.SCH 2854
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE atra-20240108_lab.xml EX-101.LAB 17995
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atra-20240108_pre.xml EX-101.PRE 11264
10 EXTRACTED XBRL INSTANCE DOCUMENT d703135d8k_htm.xml XML 3370
Mailing Address 2380 CONEJO SPECTRUM ST SUITE 200 THOUSAND OAKS CA 91320
Business Address 2380 CONEJO SPECTRUM ST SUITE 200 THOUSAND OAKS CA 91320 805-623-4244
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

IRS No.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36548 | Film No.: 24523230
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)